Yokoyama Kunio, Miyatake Shin-Ichi, Kajimoto Yoshinaga, Kawabata Shinji, Doi Atsushi, Yoshida Toshiko, Okabe Motonori, Kirihata Mitsunori, Ono Koji, Kuroiwa Toshihiko
Department of Neurosurgery, Osaka Medical College, Takatsuki, Osaka, Japan.
Radiat Res. 2007 Jan;167(1):102-9. doi: 10.1667/RR0501.1.
The efficiency of boron neutron capture therapy (BNCT) for malignant gliomas depends on the selective and absolute accumulation of (10)B atoms in tumor tissues. Only two boron compounds, BPA and BSH, currently can be used clinically. However, the detailed distributions of these compounds have not been determined. Here we used secondary ion mass spectrometry (SIMS) to determine the histological distribution of (10)B atoms derived from the boron compounds BSH and BPA. C6 tumor-bearing rats were given 500 mg/kg of BPA or 100 mg/kg of BSH intraperitoneally; 2.5 h later, their brains were sectioned and subjected to SIMS. In the main tumor mass, BPA accumulated heterogeneously, while BSH accumulated homogeneously. In the peritumoral area, both BPA and BSH accumulated measurably. Interestingly, in this area, BSH accumulated distinctively in a diffuse manner even 800 microm distant from the interface between the main tumor and normal brain. In the contralateral brain, BPA accumulated measurably, while BSH did not. In conclusion, both BPA and BSH each have advantages and disadvantages. These compounds are considered to be essential as boron delivery agents independently for clinical BNCT. There is some rationale for the simultaneous use of both compounds in clinical BNCT for malignant gliomas.
硼中子俘获疗法（BNCT）治疗恶性胶质瘤的疗效取决于肿瘤组织中硼-10（¹⁰B）原子的选择性和绝对积累。目前临床上仅能使用两种硼化合物，即双丙胺基硼（BPA）和硼氢化钠（BSH）。然而，这些化合物的详细分布尚未确定。在此，我们使用二次离子质谱法（SIMS）来确定源自硼化合物BSH和BPA的¹⁰B原子的组织学分布。给荷C6肿瘤的大鼠腹腔注射500mg/kg的BPA或100mg/kg的BSH；2.5小时后，将它们的大脑切片并进行SIMS分析。在主要肿瘤块中，BPA呈异质性积累，而BSH呈均匀性积累。在肿瘤周围区域，BPA和BSH均有可测量的积累。有趣的是，在该区域，即使距离主要肿瘤与正常脑之间的界面800微米远，BSH仍以弥散方式明显积累。在对侧脑中，BPA有可测量的积累，而BSH没有。总之，BPA和BSH各有优缺点。这些化合物被认为是临床BNCT中独立的重要硼递送剂。在恶性胶质瘤的临床BNCT中同时使用这两种化合物有一定的理论依据。
